Connect Biopharma plots phase 3 regulatory path after asthma asset hits mid-stage trial goals

A few weeks after selling off certain regional rights to monoclonal antibody (mAb) rademikibart, Connect Biopharma is back to share that mid-stage asthma trial assessing the candidate has hit its main goal, demonstrating significantly improved lung function.